small-molecule protein degraders

Taking Down Type 2 Inflammatory Disease

Sanofi scientists are working to tame over-active immune responses that drive systemic, chronic diseases


The Fight against COVID-19

As the pandemic continues, Sanofi is at the forefront of vaccine development, while carrying on the daily business of making and delivering medicines for patients

Finklea Family

Atopic Dermatitis Across the Ages

Meet three people living with AD as they share how it has affected their lives


DJSI Recognition for Sanofi’s Commitment to Society

Sanofi recognized for its performance for the 14th consecutive year

Third Quarter Results 2020

Sanofi’s financial results are published, providing a look at its business performance and the execution of its strategy

  • Camera
    Press releases
    2020-11-30MMMM DD YYYY
    Dupixent® (dupilumab) approved by European Commission as first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis
Drawing od people in front of a hospital

Improving Quality of Care in Atopic Dermatitis

This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.

Click here for more information on cookies